We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BI Shutters Ben Venue in the Face of Remediation Price Tag
BI Shutters Ben Venue in the Face of Remediation Price Tag
October 4, 2013
Boehringer Ingelheim (BI) has decided to close Ben Venue Laboratories, its beleaguered generic injectable drugmaking unit, by the end of the year, saying the subsidiary’s remediation efforts will total about $1 billion and are not worth the cost of keeping it open.